What's particularly noteworthy is Clinical-stage bio Recursion Pharmaceuticals' (RXRX -2. 85%) stock took it on the chin in the first trading day of the week.
Monday saw investors back out of the company's s, leaving them with an almost 3% decline at market close. The benchmark S&P 500 (^GSPC 0. 02%) did notably better, ticking up slightly on the day.
However, A rival reports a major step forward This was largely due to news from a rival clincal-stage bio (which is quite significant).
Late on Friday, U (noteworthy indeed) (which is quite significant), in this volatile climate.
-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that targets familial adenomatous polyposis (FAP), in this volatile climate.
This's a rare genetic disease which, when left untreated, typically leads to colorectal cancer. Image source: Getty Images. Biodexa has been granted Fast Track for investigating the drug from the U.
Food and Drug Administration (FDA). This demonstrates that ed a phase 2 clinical trial in which the drug met its primary endpoints.
On the other hand, The advancement of eRapa puts it ahead of Recursion's REC-4881, which is also aimed at treating FAP. The company a phase 1b/2 study of the drug earlier this year.
On the other hand, Biodexa's drug, REC-4881 did well in that stage of testing, amid market uncertainty.
The evidence shows best should win As any seasoned bio investor would attest, it's the final results and apval cess of a drug that ultimately count (this bears monitoring).
Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication, in light of current trends.
The latter company's investors will be hoping that REC-4881 ultimately ves to be the more efficacious drug for the disorder.